Company news
Entropy Neurodynamics Limited (ASX:ENP) news
Entropy Neurodynamics Limited news releases on 6ix. Latest, Mar 13, 2024: 2024 General Meeting Letter of Access, Notice and Proxy
Press releases — page 2
2024 General Meeting Letter of Access, Notice and Proxy
March 12, 2024
EX1 signs binding agreement to acquire Tryp Therapeutics
March 8, 2024
Appendix 4D and Half Year Report for period 31 December 2023
February 26, 2024
Further management changes and cost-reductions
November 27, 2023
Suspension from Quotation
October 2, 2023
FY2023 Appendix 4E
August 28, 2023
EX1 early stage success with in house Elastin (ELN) program
April 27, 2023
Results of Non-Renounceable Rights Issue
April 25, 2023
Exopharm Limited announces Non-Renounceable Pro Rata Rights
March 22, 2023
Disclosure Document - Rights Issue Prospectus
March 22, 2023
EX1 to Receive $1m from the Issue of Convertible Notes
March 9, 2023
EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive
March 8, 2023
Appendix 4D and Half Year Report for period 31 December 2022
February 26, 2023
Added Funding for 2023
February 12, 2023
EX1 to Receive $0.96m in Prepayment of R&D Tax Incentive
November 25, 2022
Exopharm Received R&D Tax Incentive Refund
October 26, 2022
Study results indicate exosomes safe for clinical pursuit
September 27, 2022
FY2022 Appendix 4E and Annual Report
August 30, 2022
EX1 to receive a further $0.48m in prepaid R&D Tax Incentive
July 28, 2022
EX1 to Receive over $2.7m in Prepaid R&D Tax Incentive Claim
June 16, 2022
Business Update
May 29, 2022
Response to ASX Price Query
April 27, 2022
Appendix 4D and Half Year Report for period 31 December 2021
February 25, 2022
Response to ASX Query
February 3, 2022
Exopharm and AIRM Sign MSA
January 30, 2022
Exopharm Gains US Patent for LEAP Technology
December 21, 2021
Exopharm LEAP Technology - Further Step Towards US Patent
September 26, 2021
Exopharm LEAP Technology - Second Commercial Collaboration
September 8, 2021
FY2021 Appendix 4E and Annual Report
August 29, 2021
Exopharm LEAP Exosome Technology Granted 1st National Patent
June 3, 2021
Exopharm Receives Firm Commitments to Raise $12 million
April 19, 2021
Positive PLEXOVAL II Phase 1 Clinical Trial Results
April 5, 2021
Preclinical Data from Osteoarthritis Animal Study
April 1, 2021
Appendix 4D and Half Year Financial Report
February 25, 2021
Response to ASX Price and Volume Query
February 8, 2021
Quarterly Report and Appendix 4C
January 28, 2021
September Quarterly Report and Appendix 4C
October 26, 2020
Exopharm raises $10m in well supported Placement
August 26, 2020
June Quarterly Report and Appendix 4C
July 30, 2020
Added IP empowers Exopharms engineered exosome pipeline
June 11, 2020
Shareholder Update
May 27, 2020
Plexaris product engineered to deliver anti-cancer drug
May 24, 2020
March Quarterly Report and Appendix 4C
April 24, 2020
PLEXOVAL I study disrupted by the Covid-19 response
March 31, 2020
Appendix 4D and Interim Financial Report
February 20, 2020
Cevaris testing shows positive results in bladder control
February 19, 2020
Cevaris testing shows positive results in models of ED
February 18, 2020
Independent Plexaris and Cevaris testing
February 11, 2020
December Quarterly Report and Appendix 4C
January 28, 2020
Key Management Contracts Extended
November 25, 2019